Skip to main content

576 publications

Name Date Type Actions

Monthy information regarding the total number of voting rights and shares making of the share capital - April 2024

As per articles L2338II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

06/05/2024 Voting rights

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

29/04/2024 Public releases

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

24/04/2024 Public releases

Monthly information regarding the total number of voting rights – March 2024

As per articles L2338II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

04/04/2024 Voting rights

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

20/03/2024 Public releases

Monthly information regarding the total number of voting rights – February 2024

As per articles L2338II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »As per articles L2338II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

05/03/2024 Voting rights

Monthly information regarding the total number of voting rights – January 2024

As per articles L2338II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

 

02/02/2024 Voting rights

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

24/01/2024 Public releases

Monthly information regarding the total number of voting rights – December 2023

As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

04/01/2024 Voting rights

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

26/10/2023 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - September 2023

As per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

04/10/2023 Voting rights

Monthly information regarding the total number of voting rights and shares making of the share capital - August 2023

As per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

12/09/2023 Voting rights

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

07/09/2023 Public releases

Monthly information regarding the total number of voting rights - July 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

22/08/2023 Voting rights

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

20/04/2023 Public releases

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

13/04/2023 Public releases

Monthly information regarding the total number of voting rights - March 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

05/04/2023 Voting rights

Monthly information regarding the total number of voting rights - April 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

05/04/2023 Voting rights

Monthly information regarding the total number of voting rights - May 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

05/04/2023 Voting rights

Monthly information regarding the total number of voting rights - June 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

05/04/2023 Voting rights

Buyback programs – March 2023

Monthly communication regarding buyback programs

05/04/2023 Monthly communication regarding buyback programs

Clone of Buyback programs – April 2023

Monthly communication regarding buyback programs

05/04/2023 Monthly communication regarding buyback programs

Buyback programs – May 2023

Monthly communication regarding buyback programs

05/04/2023 Monthly communication regarding buyback programs

Buyback programs – June 2023

Monthly communication regarding buyback programs

05/04/2023 Monthly communication regarding buyback programs

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

23/03/2023 Public releases

Monthly information regarding the total number of voting rights - February 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the « Reglement Général de L’Autorité des Marchés Financiers »

06/03/2023 Voting rights

Monthly information regarding the total number of voting rights - January 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

07/02/2023 Voting rights

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

18/01/2023 Public releases

Monthly information regarding the total number of voting rights - december 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

05/01/2023 Voting rights

Monthly information regarding the total number of voting rights ans shares making of the share capital - november

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

08/12/2022 Voting rights

Monthly communication regarding buyback programs - october 2022

10/11/2022 Voting rights

First nine months 2022 sales: €405M

In line with year-end outlook

12/10/2022 Public releases

Monthly communication regarding buyback programs - September 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

05/10/2022 Voting rights

2022 HALF YEAR RESULTS Additional information on the Group’s strategy

Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook.

23/09/2022 Public releases , Half Year Report

2022 HALF YEAR RESULTS

Sales: €271m (up 6.0% as reported)
Essentials sales: €154m (up 9.8% as reported)
EBIT before depreciation of acquired assets: €52m (19.0% of sales)
Net income - Group share: €21m (7.9% of sales)
EBITDA: €62m (22.9% of sales)

15/09/2022 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - August 2022

As per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

06/09/2022 Voting rights

Monthly information regarding the total number of voting rights and shares making of the share capital - July 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

22/08/2022 Voting rights

H1 2022 Sales

H1 2022 Sales: €271m, up 6.1%
+2.0% on a like-for-like basis
H1 2022 Essentials Sales: €154m, up 9.8%
+6.8% on a like-for-like basis

20/07/2022 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - june 2022

as per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

05/07/2022 Voting rights

Buyback programs - may 2022

Monthly communication regarding buyback programs

03/06/2022 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - may 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

03/06/2022 Voting rights

Monthly information regarding the total number of voting rights and shares making of the share capital - april 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

05/05/2022 Voting rights

Buyback programs - april 2022

Monthly communication regarding buyback programs

05/05/2022 Monthly communication regarding buyback programs

Availability of the 2021 universal registration document

Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022.

22/04/2022 Public releases

Q1 2022 SALES: €135M

Q1 2022 SALES: €135M
(UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES)
Q1 2022 ESSENTIALS SALES: €77M
(UP 8.1% AS REPORTED, UP 5.5 AT CONSTANT EXCHANGE RATES)

13/04/2022 Public releases

Buyback programs - march 2022

Monthly communication regarding buyback programs

06/04/2022 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares - march 2022

Monthly information regarding the total number of voting rights and shares making of the share capital

as per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

06/04/2022 Voting rights

2021 Annual results

ALL FINANCIAL INDICATORS UP.
Annual sales: €521m (up 21.9% as reported).
Essentials sales: €296m (up 34.0% as reported).
EBIT before depreciation of acquired assets: €101m (up 54.5%).
Net income - Group share: €63m (up 226.9%).

24/03/2022 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital- february 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

04/03/2022 Voting rights

Buyback programs - february 2022

Buyback programs - February 2022

04/03/2022 Monthly communication regarding buyback programs

Buyback programs - January 2022

07/02/2022 Monthly communication regarding buyback programs

Double-digit growth in 2021

Total Group Sales: €521 million (up 21.9% as reported)
Annual Sale of Essential products: €296 million (up 34.0% as reported)

20/01/2022 Public releases

Clone of Monthly information regarding the total number of voting rights and shares making of the share capital

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

06/01/2022 Voting rights

Monthly information regarding the total number of voting rights and shares making of the share capital

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

06/01/2022 Voting rights

Programme de rachat - Décembre 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres.

04/01/2022 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - November 2021

As per article 223.16 of the « Règlement Général de l’Autorité des marchés financiers »

06/12/2021 Voting rights

Programme de rachat - November 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

06/12/2021 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - October 2021

08/11/2021 Voting rights

Programme de rachat - October 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

08/11/2021 Monthly communication regarding buyback programs

Third quarter revenues: €132 million

14/10/2021 Public releases

Programme de rachat - September 2021

07/10/2021 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - September 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

07/10/2021 Voting rights

Monthly information regarding the total number of voting rights and shares making of the share capital - July 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

06/09/2021 Voting rights

Programme de rachat - August 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

06/09/2021 Monthly communication regarding buyback programs

Programme de rachat - July 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

24/08/2021 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - July 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

24/08/2021 Voting rights

2021 first half results

2021 Half year results

29/07/2021 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - June 2021

05/07/2021 Voting rights

Programme de rachat - May 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

05/07/2021 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - April 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

04/06/2021 Voting rights

Programme de rachat - May 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

03/06/2021 Monthly communication regarding buyback programs

Programme de rachat - April 2021

05/05/2021 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - April 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

05/05/2021 Voting rights

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

28/04/2021 Public releases

Q1 2021 sales

Q1 2021 sales : €128M (up 28% at constant exchange rates, up 24% as reported)
Q1 2021 essential sales : €72.6M (up 38% at constant exchange rates, up 36% as reported)

15/04/2021 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - March 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

07/04/2021 Voting rights

Programme de rachat - March 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

07/04/2021 Monthly communication regarding buyback programs

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m

01/04/2021 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - February 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

05/03/2021 Voting rights

Programme de rachat - February 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

05/03/2021 Monthly communication regarding buyback programs

Vetoquinol wins the Animal Pharm’s award for best European company 2020

February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm.

08/02/2021 Public releases

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

08/02/2021 press release excluding results

Monthly information regarding the total number of voting rights and shares making of the share capital - January 2021

04/02/2021 Voting rights

Programme de rachat - January 2021

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

04/02/2021 Monthly communication regarding buyback programs

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.

21/01/2021 Public releases

Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

18/01/2021 Public releases

Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia

January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health.

11/01/2021 Public releases

Programme de rachat - December 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

07/01/2021 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - December 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

07/01/2021 Voting rights

Programme de rachat - November 2020

03/12/2020 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital - November 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

03/12/2020 Voting rights

Monthly information regarding the total number of voting rights and shares making of the share capital - October2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

04/11/2020 Voting rights

Programme de rachat - October 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

04/11/2020 Monthly communication regarding buyback programs

Q3 2020 sales: €114.5 million* (Up 14.3%)

Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year.

15/10/2020 Public releases

Programme de rachat - September 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

05/10/2020 Monthly communication regarding buyback programs

Monthly information regarding the total number of voting rights and shares making of the share capital -September 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

 

05/10/2020 Voting rights

VETOQUINOL, SNGTV and FARMVETSYSTEMS sign a partnership agreement to offer a common, innovative digital solution to the veterinary healthcare market. September 28th, 2020 (Paris, France) VETOQUINOL, FARMVET SYSTEMS and SNGTV have signed a partnership agreement aimed at offering a common solution highlighting the complementarity of their two software, VetIMPRESS and Vetélevage to farm vets. Aware of their shared philosophy aimed at optimizing vets actions thanks to new digital technologies, they are pooling these two software programs to strengthen the role of farm vets in animal health and welfare.

28/09/2020 Public releases

Vetimpress delivering digital solutions to farm vets with a growing network of partnerships

September 21st, 2020 (Northern Ireland) – VetIMPRESS the secure data management platform has recently implemented a series of integrations, reinforcing its position as a leading source of information for farm animal vets. The platform has grown its connections to over 100 external sources across 10 countries. The partnerships are set to improve connectivity across the industry, providing a single source of truth to better inform ethical, safe and productive veterinary decisions.
 

21/09/2020 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital -Aout 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

03/09/2020 Voting rights

Programme de rachat - August 2020

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

03/09/2020 Monthly communication regarding buyback programs